80 related articles for article (PubMed ID: 35710585)
1. Clinically relevant immune subtypes based on alternative splicing landscape of immune-related genes for lung cancer advanced PPPM approach.
Li N; Jia W; Wang J; Shao Q; Feng X; Li Z; Sun W; Kang M; Hu D; Xing L; Zhan X
EPMA J; 2024 Jun; 15(2):345-373. PubMed ID: 38841624
[TBL] [Abstract][Full Text] [Related]
2. Identification of an antigen-presenting cells/T/NK cells-related gene signature to predict prognosis and CTSL to predict immunotherapeutic response for lung adenocarcinoma: an integrated analysis of bulk and single-cell RNA sequencing.
Huang L; Lou N; Xie T; Tang L; Han X; Shi Y
Cancer Immunol Immunother; 2023 Oct; 72(10):3259-3277. PubMed ID: 37458771
[TBL] [Abstract][Full Text] [Related]
3. Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma.
Li S; Wang W; Yu H; Zhang S; Bi W; Sun S; Hong B; Fang Z; Chen X
BMC Cancer; 2023 Nov; 23(1):1115. PubMed ID: 37974107
[TBL] [Abstract][Full Text] [Related]
4. Development of an invasion score based on metastasis-related pathway activity profiles for identifying invasive molecular subtypes of lung adenocarcinoma.
Han T; Liu Y; Zhou J; Guo J; Xing Y; Xie J; Bai Y; Wu J; Hu D
Sci Rep; 2024 Jan; 14(1):1692. PubMed ID: 38243040
[TBL] [Abstract][Full Text] [Related]
5. A single-cell characterised signature integrating heterogeneity and microenvironment of lung adenocarcinoma for prognostic stratification.
Xu J; Zhang Y; Li M; Shao Z; Dong Y; Li Q; Bai H; Duan J; Zhong J; Wan R; Bai J; Yi X; Tang F; Wang J; Wang Z
EBioMedicine; 2024 Apr; 102():105092. PubMed ID: 38547579
[TBL] [Abstract][Full Text] [Related]
6. The prognosis, chemotherapy and immunotherapy efficacy of the SUMOylation pathway signature and the role of UBA2 in lung adenocarcinoma.
Yu L; Lin N; Ye Y; Zhuang H; Zou S; Song Y; Chen X; Wang Q
Aging (Albany NY); 2024 Feb; 16(5):4378-4395. PubMed ID: 38407971
[TBL] [Abstract][Full Text] [Related]
7. Identification of endoplasmic reticulum stress-related signature characterizes the tumor microenvironment and predicts prognosis in lung adenocarcinoma.
Wan L; Chen Z; Yang J; Wu G; Xu Y; Cui J; Zhao X
Sci Rep; 2023 Nov; 13(1):19462. PubMed ID: 37945620
[TBL] [Abstract][Full Text] [Related]
8. A novel recurrence-associated metabolic prognostic model for risk stratification and therapeutic response prediction in patients with stage I lung adenocarcinoma.
Liu C; Wang S; Zheng S; Wang X; Huang J; Lei Y; Mao S; Feng X; Sun N; He J
Cancer Biol Med; 2021 Apr; 18(3):734-49. PubMed ID: 33856140
[TBL] [Abstract][Full Text] [Related]
9. Diverse regulated cell death modes predict the immune microenvironment and drug sensitivity in lung adenocarcinoma.
You L; Xin Z; Zhou X; Na F; Zhou J; Ying B
J Cell Physiol; 2023 Nov; 238(11):2570-2585. PubMed ID: 37842875
[TBL] [Abstract][Full Text] [Related]
10. Role of Protein Tyrosine Phosphatase Receptor Type E (PTPRE) in Chemoresistant Retinoblastoma.
Mohren L; Doege A; Miroschnikov N; Dräger O; Busch MA; Dünker N
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674157
[TBL] [Abstract][Full Text] [Related]
11. Identification of four metabolic subtypes and key prognostic markers in lung adenocarcinoma based on glycolytic and glutaminolytic pathways.
Zhang J; Wang X; Song C; Li Q
BMC Cancer; 2023 Feb; 23(1):152. PubMed ID: 36782138
[TBL] [Abstract][Full Text] [Related]
12. Integrated analysis of bulk and single-cell RNA-seq reveals the role of MYC signaling in lung adenocarcinoma.
Hao L; Chen Q; Chen X; Zhou Q
Front Genet; 2022; 13():1021978. PubMed ID: 36299592
[TBL] [Abstract][Full Text] [Related]
13. Identification of an inflammatory response signature associated with prognostic stratification and drug sensitivity in lung adenocarcinoma.
Song C; Lu Z; Lai K; Li D; Hao B; Xu C; Pan S; Li N; Geng Q
Sci Rep; 2022 Jun; 12(1):10110. PubMed ID: 35710585
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis reveals the potential value of inflammatory response genes in the prognosis, immunity, and drug sensitivity of lung adenocarcinoma.
Song C; Pan S; Li D; Hao B; Lu Z; Lai K; Li N; Geng Q
BMC Med Genomics; 2022 Sep; 15(1):198. PubMed ID: 36117156
[TBL] [Abstract][Full Text] [Related]
15. Development and Validation of a Machine Learning Prognostic Model of m5C Related immune Genes in Lung Adenocarcinoma.
Cao X; Ji Y; Li J; Liu Z; Chen C
Cancer Control; 2024; 31():10732748241237414. PubMed ID: 38537151
[TBL] [Abstract][Full Text] [Related]
16. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
17. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
18. Immune- and Stemness-Related Genes Revealed by Comprehensive Analysis and Validation for Cancer Immunity and Prognosis and Its Nomogram in Lung Adenocarcinoma.
Chen M; Wang X; Wang W; Gui X; Li Z
Front Immunol; 2022; 13():829057. PubMed ID: 35833114
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
